New combo aims to free CML patients from daily pills

NCT ID NCT03610971

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding ruxolitinib to a standard tyrosine kinase inhibitor (TKI) can help people with chronic myeloid leukemia (CML) stop their medication for longer. Participants had previously tried stopping a TKI but relapsed. The study enrolls 24 adults and measures how many remain in remission without treatment after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib (Jakafi) plus a tyrosine kinase inhibitor (imatinib, dasatinib, nilotinib, or bosutinib)
What this could lead to: If successful, this could help some CML patients stay off daily medication for longer periods, reducing side effects and treatment burden.
What could go wrong: This is a small, early-phase study with only 24 participants. The combination may cause more side effects, and not everyone may achieve treatment-free remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid, Chronic-Phase

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA, CHRONIC PHASE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA

Contacts and locations

Locations

David H. Koch Center for Cancer Care at Memorial Sloan Kettering

New York, New York, 10021, United States
Duke University Hospital

Durham, North Carolina, 27710, United States
Emory -Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Froedtert Hospital & the Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Memorial Sloan Kettering - Bergen

Montvale, New Jersey, 07645, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.